NAUT
NASDAQNautilus Biotechnology Inc.
News · 26 weeks34+100%
2025-12-282026-06-21
Mix1490d
- Insider6(43%)
- SEC Filings5(36%)
- Earnings2(14%)
- Other1(7%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Posard Matthew L.4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
- INSIDERSEC Form 4 filed by Director Akinsanya Karen4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
- INSIDERSEC Form 4 filed by Director Nazem Farzad4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
- INSIDERSEC Form 4 filed by Director Mcilwain Matthew S4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
- INSIDERSEC Form 4 filed by Director Epperly Melissa B,4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
- SECNautilus Biotechnology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Nautilus Biotechnology, Inc. (0001808805) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.SCHEDULE 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)
- INSIDERLarge owner Ah Equity Partners Bio Ii, L.L.C. sold $11,750,000 worth of shares (5,000,000 units at $2.35) (SEC Form 4)4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
- SECSEC Form DEFA14A filed by Nautilus Biotechnology Inc.DEFA14A - Nautilus Biotechnology, Inc. (0001808805) (Filer)
- SECSEC Form DEF 14A filed by Nautilus Biotechnology Inc.DEF 14A - Nautilus Biotechnology, Inc. (0001808805) (Filer)
- SECSEC Form 10-Q filed by Nautilus Biotechnology Inc.10-Q - Nautilus Biotechnology, Inc. (0001808805) (Filer)
- PRNautilus Biotechnology Reports First Quarter 2026 Financial ResultsSEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Business Highlights Initiated our Iterative Mapping Early Access Program, enabling broader access to our validated Tau proteoform assay, with Baylor College of Medicine as our first customer in a National Institutes of Health-funded cancer study.Advanced processing and analysis of Tau proteoform samples from collaborators, supporting platform validation and future scientific publications.Appointed Amber Faust as Vice President of Global Sale
- SECNautilus Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nautilus Biotechnology, Inc. (0001808805) (Filer)
- PRNautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026SEATTLE, April 09, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the first quarter 2026 before market open on Tuesday, April 28, 2026. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and its
- PRNautilus Biotechnology to Participate in the Investor Summit Group Virtual ConferenceSEATTLE, March 24, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Investor Summit Group Virtual Conference. Nautilus' management is scheduled to present on Wednesday, March 25, 2026, at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time. Interested parties may access live and archived webcasts of the presentations on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos,
- PRNautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform• Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit• NIH-funded project leverages collaborators' expertise in single-molecule proteomics and protein isoform quantification to advance high-resolution cancer isoform analysis SEATTLE, March 18, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering single-molecule proteome analysis, today announced Baylor College of Medicine as the first customer of Nautilus' Iterative Mapping Early Access Program. Through a National Institutes of Health (NIH) U01-funded study, Baylor will leverage Nautilus' novel
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.SCHEDULE 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)
- INSIDERCEO, President, and Secretary Patel Sujal M bought $65,238 worth of shares (25,000 units at $2.61), increasing direct ownership by 0.24% to 10,366,721 units (SEC Form 4)4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
- INSIDERSEC Form 4 filed by CFO and Treasurer Mowry Anna4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientist Mallick Parag4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
- INSIDERSEC Form 4 filed by CEO, President, and Secretary Patel Sujal M4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
- INSIDERSEC Form 4 filed by Chief People Officer Weld Gwen E4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
- INSIDERSEC Form 4 filed by Senior VP, Product Development Sankar Subramanian4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
- INSIDERSEC Form 4 filed by General Counsel Murphy Matthew B.4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
- INSIDERSEC Form 4 filed by Chief Marketing Officer Suzuki Kentaro4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
NAUT FAQ
7 questionsWhat does Nautilus Biotechnology Inc. do?
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the human proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company is headquartered in Seattle, Washington.Where does NAUT stock trade?
Nautilus Biotechnology Inc. (NAUT) is listed on NASDAQ.What sector and industry is NAUT in?
Nautilus Biotechnology Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.When did Nautilus Biotechnology Inc. go public?
Nautilus Biotechnology Inc. (NAUT) completed its IPO in 2020.What are analysts saying about NAUT?
Nautilus Biotechnology Inc. has had 7 recent analyst actions on file. The most recent action was from Goldman: Sell with a $175.00 price target on 2024-12-05.What companies are similar to NAUT?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare NAUT side-by-side with any of them on Quantisnow.How can I track NAUT on Quantisnow?
Quantisnow aggregates Nautilus Biotechnology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NAUT to receive live email and push alerts on every new disclosure.